25 January 2017

Sales Results Exceed Expectations for Faulding® GlucoControl™

Highlights

• Release of first Faulding® GlucoControl™ sales following marketing launch in late September 2016
• 2016 Q4 Sales achieved over 40,000 sachets through pharmacy sales in Australia
• Faulding® GlucoControl™ is now available in approximately 800 pharmacies across Australia
• Key Opinion Leaders providing positive feedback on Faulding® GlucoControl™

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on its portfolio company, Omni Innovation, the medical technology company focused on medical nutrition.

Positive Initial Sales following Marketing launch

In September 2016 marketing for Faulding® GlucoControl™ commenced and initial sales volumes have been very positive with over 40,000 sachets sold during Q4 2016. In addition, Faulding® GlucoControl™ is now widely available in 800 specialist and independent pharmacies across Australia, including in Australia’s leading health focused retail pharmacy chain.

The sales of Faulding® GlucoControl™ are expected to grow based on increased consumer numbers, and establishment of continual use, as the pre-meal drink concept is integrated into routine type 2 diabetes management plans. Positive initial feedback from Key Opinion Leaders in the field of nutritional management is establishing a clear message to health care professionals and pharmacists regarding Faulding® GlucoControl™. As more health care professionals introduce Faulding® GlucoControl™ into their clinical practices, a sustained pattern of consumer utilisation and sachet sales is expected.

The positive initial sales in Australia provide a platform for continued sales growth in Australia and support product validation for expansion into offshore markets. Additionally, it assists in the development of a distribution platform for the pipeline of new products being developed by Omni Innovation. The new products currently under development are products that are scientifically validated and target those people with chronic and lifestyle diseases.

“EVE is encouraged by this initial sales data and is looking forward to the next twelve months of company growth with increasing sales in Australia plus the addition of international sales from the UK, Asia and the US.” said Ben Rohr, Investment Director, EVE Investments.

Ends

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments
About Omni Innovation
Omni Innovation is a private Melbourne based company developing evidence-based dietary interventions to improve the lives of people with common chronic diseases such type-2 diabetes and low blood pressure (hypotension).

In 2016, Faulding® GlucoControl™ was launched by the Company as its maiden product for use in the dietary management of type 2 diabetes and pre-diabetes.

For more information, please visit www.obinnovation.com.au

For more information:

Bill Fry
Executive Director
+61 8 6465 5500
billf@eveinvestments.com.au